-
Clinical Ophthalmology
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
First experience with BAK-free travoprost 0.004% in topical glaucoma medication
Original Research
(4559) Total Article Views
Authors: Gado AS, Macky TA
Published Date December 2011 Volume 2012:6 Pages 1 - 4
DOI: http://dx.doi.org/10.2147/OPTH.S24983
Ahmed Salah Gado, Tamer Ahmed MackyDepartment of Ophthalmology, Cairo University, Cairo, Egypt
Objectives: Benzalkonium chloride (BAK)-free travoprost 0.004% (Travatan Z®, Alcon Laboratories, Inc, Fort Worth, TX) is a new formulation that was developed with the aim of creating a formulation of travoprost that would maintain the intraocular pressure (IOP)-lowering efficacy and have an improved overall safety profile, particularly improved ocular surface tolerability.
Methods: Thirty newly diagnosed primary open-angle glaucoma (POAG) patients were treated with BAK-free travoprost 0.004%. IOP readings were recorded at baseline before initiating treatment, at 4–6 weeks, and after 12 weeks of starting treatment. In addition, patient demographics, subjective symptoms (ie, burning, foreign-body sensation, itching, and stinging), and objective clinical signs such as conjunctival hyperemia were collected. Subjective symptoms were evaluated using a four-point scale ranging from “no symptoms,” “mild symptoms,” “moderate symptoms” to “severe symptoms.” As for clinical signs, severity of conjunctival hyperemia was evaluated. All other adverse events were collected.
Results: BAK-free travoprost 0.004% provided an IOP decrease in all patients, with an overall mean of 28.3 ± 2.1 mmHg at baseline to a mean of 18.7 ± 1.6 mmHg at 4–6 weeks, and a mean of 18.4 ± 1.4 mmHg after 12 weeks. Both subjective symptoms and objective clinical signs were very few after treatment.
Conclusion: The results demonstrate that BAK-free travoprost 0.004% is an effective, well tolerated, and safe medication in POAG patients.
Keywords: primary open-angle glaucoma, POAG, benzalkonium chloride, Travatan
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- Interested in being a peer-reviewer?
Click here to register.
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, University of Texas Health Science Center, San Antonio.
- Insight into 144 patients with ocular vascular events during VEGF antagonist injections
- Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
- Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives
- Dexmedetomidine sedation in painful posterior segment surgery